Generic Name: inotuzuma ozogamicin

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Wyeth-Pfizer

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Besponsa is an antibody-drug conjugate approved for adults with B cell acute lymphoblastic leukemia that does not respond to prior treatment.

General Info

Besponsa is an engineered antibody that targets the CD22 protein on B cells combined with a small molecule drug that kills cancer cells. The conjugate enters tumor cells and releases the drug, which causes DNA breaks that stop cell multiplication.

The INO-VATE ALL trial showed that 36 percent of patients treated with Besponsa achieved complete remission and normalization of blood cell counts, compared with 17 percent of those treated with chemotherapy.


Dosing Info:

Besponsa is administered by intravenous infusion, usually on three days in a monthly cycle.

Side Effects

Common side effects include fatigue, fever, nausea, headache and abdominal pain. Besponsa can cause depletion of red blood cells (anemia), white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and easy bleeding. The Besponsa label includes a warning about serious liver toxicity. Besponsa may cause fetal harm if used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: November 29, 2018